Clinical Trials Browser

Active not recruiting × avapritinib × Myeloid × Clear all

NCT03731260 2025-09-23

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Phase 2 Active not recruiting

Mastocytosis, Systemic